Skip to content

Collection of Circulating Biomarkers in Pancreatic Cancer

Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05743049
Enrollment
30
Registered
2023-02-24
Start date
2023-02-27
Completion date
2028-01-15
Last updated
2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer

Brief summary

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Interventions

OTHERObtaining blood for analysis of various circulating biomarkers

4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

Sponsors

Abramson Cancer Center at Penn Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma * The subject must be a patient of the University of Pennsylvania * The subject must be able to provide informed consent * The subject must be 18 years of age or older

Exclusion criteria

. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Design outcomes

Primary

MeasureTime frame
To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.Through study completion, an average of 1 year

Secondary

MeasureTime frame
To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.Through study completion, an average of 1 year
To integrate the data and specimens to permit the most informative clinical-biologic research platform.Through study completion, an average of 1 year

Countries

United States

Contacts

CONTACTLiudmila Mazaleuskaya, PhD
mazali@pennmedicine.upenn.edu267-455-9141
CONTACTMark O'Hara, MD
Mark.OHara@pennmedicine.upenn.edu215-360-0919
PRINCIPAL_INVESTIGATORMark O'Hara, MD

Abramson Cancer Center, University of Pennsylvania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026